Answers are grounded in this paper and cite their sources.
Myasthenia gravis (MG) is a rare antibody-mediated disorder of the neuromuscular junction with an annual incidence ranging from 0.5 to 3 per 100.000 patients [ 4 ]. A fluctuating, activity-dependent weakness predominantly affects ocular, bulbar, and/or limb and trunk skeletal muscles. Treatment comprises symptomatic (cholinesterase inhibitors) as well as immunosuppressive treatment.
No takes yet. Share an insight, caveat, or question.
Mück et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: